Bispecific Antibodies for Targeting Alzheimer's Disease in the Brain

This patent describes special antibodies designed to cross into the brain and target amyloid-beta, a protein linked to Alzheimer's disease.

What it covers

This patent describes special antibodies that are 'bispecific,' meaning they are engineered to attach to two different targets at the same time. One target is human A-beta, a protein linked to Alzheimer's disease. The other target is the human transferrin receptor, a protein found on the blood-brain barrier, which is the protective shield around the brain. The patent provides these specific antibodies and methods for using them, likely to help deliver treatment to the brain for conditions like Alzheimer's disease.

What it doesn't cover

• —Antibodies that only target one specific protein (monospecific antibodies), rather than two different ones simultaneously.
• —Bispecific antibodies that target different combinations of proteins, not specifically human A-beta and the human transferrin receptor.
• —Methods of treating Alzheimer's disease that do not involve using antibodies to cross the blood-brain barrier via the transferrin receptor.
• —Other types of treatments for neurodegenerative diseases, such as small molecule drugs or gene therapies, that are not antibody-based.
• —Antibodies that target A-beta but do not use the transferrin receptor to enter the brain.
• —Antibodies that target the transferrin receptor but do not also target A-beta.

The clever bit

The clever part is designing a single antibody that can both sneak past the brain's defenses using the transferrin receptor and then specifically attack the amyloid-beta proteins associated with Alzheimer's disease.

Why it matters

Alzheimer's disease affects millions, and a major challenge in treating it is getting medicines past the blood-brain barrier, a natural defense that protects the brain. This type of antibody aims to overcome that barrier, potentially opening new ways to deliver treatments directly to the brain to target amyloid-beta plaques.

Real-world examples

• 1.Antibody-based therapies for neurodegenerative diseases
• 2.Drugs designed to cross the blood-brain barrier
• 3.Next-generation Alzheimer's treatments